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Few studies have correlated serum biomarkers with renal histology, the gold standard for renal activity, in lupus nephritis (LN). We
tested a panel of autoantibodies and complement at the time of kidney biopsy and after treatment. Anti-dsDNA, anti-nucleosome,
anti-ribosome P, and anti-C1q antibodies and C3/C4 were measured in 107 patients with LN at the time of renal biopsy and after
6–12 months and were correlated with clinical/histological parameters. At multivariate analysis, high titers of anti-C1q antibodies
or of anti-dsDNA antibodies (𝑃 = 0.005, OR = 8.67, CI: 2.03–37.3) were the independent predictors that discriminate proliferative
from nonproliferative LN. All the immunological parameters, except anti-ribosome, showed a significant correlation with activity
index but not with chronicity index. Only anti-C1q showed a significant correlation with the amount of proteinuria (𝑅 = 0.2,
𝑃 = 0.03). None of the immunological parameters were predictive of remission at 6 and 12 months. We found that anti-C1q alone
or in combination with anti-dsDNA emerged as the most reliable test in differentiating proliferative and nonproliferative LN. Anti-
C1q was the only test correlated with the clinical presentation of LN. After treatment, the titre of the autoantibodies was significantly
reduced, but none was predictive of remission.
1. Introduction
Lupus nephritis (LN) is one of the most frequent manifesta-
tions of Systemic Lupus Erythematosus (SLE) and represents
a major determinant of disease morbidity and mortality [1].
Its clinical course is often characterized by flares of activity
alternated with periods of quiescence, generally induced by
therapy [2].The identification of noninvasive biomarkersmay
help to predict the renal involvement at diagnosis and mon-
itor relapses of LN during the follow-up. Many studies have
tested the value of a number of autoantibodies for predicting
or confirming the diagnosis of renal flares with contrasting
results. Some [3–5] but not all studies [6] have demonstrated
that anti-dsDNA antibodies (anti-dsDNA) and complement
fractions may be useful in assessing the disease and the renal
activity. One paper [7] and a recent review [8] concluded that
anti-nucleosome antibodies have high prevalence in severe
LN but are of limited help in differentiating active from
inactive LN. A number of cross sectional studies found that
antiC1q antibodies (antiC1q) have a significant association
with renal involvement [9–15]. In our previous paper on a
large cohort of SLE patients evaluated prospectively for 6
years, we demonstrated that renal exacerbations seem to be
quite improbable in the presence of normal values of C3, C4,
anti-dsDNA, anti-C1q, and that anti-C1q was slightly better
than the other tests to confirm the clinical activity of LN [16].
Noteworthy, in the vast majority of studies the diagnosis
of LN flares relies on variable clinical definitions based on
activity of urine sediment, amount of proteinuria, and deteri-
oration of renal function, whilst the “gold standard” for the
diagnosis of renal activity is represented by renal biopsy. In
this prospective study, serum samples at renal biopsy and
after the induction therapy of 107 LN patients were tested for
a panel of autoantibodies (including anti-dsDNA, anti-C1q,
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anti-nucleosome, anti-ribosome antibodies, and C3 and C4
complement fractions) to investigate their association with
the clinical and histological data.
2. Patients and Methods
One hundred and seven patients with SLE, diagnosed accord-
ing to the American College of Rheumatology criteria [17]
(94 females, 13 males) at admission in two Italian Renal Units
(Fondazione Ospedale Maggiore and Azienda Ospedaliera
Ospedale San Carlo Borromeo, Milano) to undergo renal
biopsy for assessment of LN, entered the study. The renal
biopsies were classified following the ISN/RNP classification
[18]. Activity and chronicity indices were calculated accord-
ing to Austin et al. [19].
Sera at renal biopsy were tested for a panel of auto
antibodies including anti-dsDNA and anti-C1q, anti-
nucleosome, and anti-ribosome antibodies as well as C3 and
C4 complement fractions.
The study does not need an ethical approval. We have
obtained an informed consent to participate in the study from
all the patients involved.
2.1. Objectives. The aim of this study was to assess the
performance of these tests in predicting:
(a) the histological classes of lupus nephritis,
(b) the activity and chronicity index at renal biopsy,
(c) the clinical feature of LN at renal biopsy,
(d) the response of lupus nephritis at 3, 6, and 12 months
after the beginning of the induction therapy.
2.2. Laboratory Investigations. Anti-dsDNA antibodies were
measured by a commercial quantitative ELISA (Varelisa anti-
dsDNA Antibodies, Phadia GmbH, Freiburg, Germany) and
C3 and C4 plasma levels by nephelometry (Nephelometer
Analyser II, Behring, Marburg GmbH, Germany).
Anti-C1q antibodies were detected using a home-made
ELISA as described by Sinico et al. [11].
Anti-nucleosome antibodies were measured by ELISA
according to manufacturer instructions using Quanta Lite
Chromatin assay (INOVA diagnostics, Inc., San Diego, CA,
USA) [20].
Anti-ribosome P antibodies were measured by ELISA
according to manufacturer instructions using Quanta Lite
Ribosomal P assay (INOVA diagnostics, Inc., San Diego, CA,
USA).
2.3. Definition of Activity. At each clinical examination the
activity of LN was classified as follows [2]:
0 = complete renal remission: normal renal function
for at least 6 months, proteinuria <0.5 g/24 h, and
urinary red blood cells <5/hpf;
1 = partial renal remission: for nephritic flare:
improvement of at least 30% of serum creatinine but
persistence of active urinary sediment; for proteinuric
flares improvement of 50% of proteinuria;
2 = nephritic flare: increase of 30% of serum creati-
nine over the basal value and active urinary sediment
(>10 red blood cells/hpf, cellular casts) with or with-
out an increase in proteinuria;
3 = proteinuric flare: increase of proteinuria of at
least 2 g/day in patients with non nephrotic syndrome
or the doubling of nephrotic proteinuria with stable
renal function;
4 = persistent renal activity: the lack of achievement
of remission after induction therapy.
3. Statistical Analysis
Mean and standard deviation, together with median and
interquartile (IQ) range (25∘–75∘ percentile) were used as
descriptive statistics. For continuous variables, the nonpara-
metric Wilcoxon test was used for assessing any difference
between the two groups of patients, while the chi-square
test was used for dichotomized variables. The Spearman
correlation was used to analyse correlation.
Multivariate logistic regression analysis has been used
to find predictors of histological classes of lupus nephritis
and for the predictors of complete renal response after
the beginning of induction therapy. Odds ratios (OR) and
their 95% confidence interval (CI) for the covariates were
derived as the antilogarithm of the regression coefficients.
Multivariate linear regression analysis was used to predict the
activity index at renal biopsy.
The statistical package S-Plus (MathSoft Inc.) was used for
all the analyses and plots.
4. Results
The characteristics of the patients at renal biopsy are reported
in Table 1. The 107 patients received 111 renal biopsies (4
patients, 2 biopsies). The mean age at diagnosis of SLE was
35.3 ± 14.2 years, (median 34) and that at renal biopsy was
36.4 ± 13.9 years (median 36). The mean time between the
diagnosis of SLE and that of renal involvement was 5.1 ± 6.5
years, (median 3 years). In 45 patients, renal involvement was
present at diagnosis of SLE.
Considering that a preliminary analysis demonstrated
no significant differences in the mean values of C3, C4,
anti-dsDNA, anti-C1q, anti-nucleosome, and anti-ribosome
antibodies between class II and class V and between class
III and Class IV LN (data not shown), the subsequent
analysis was performed comparing Class II plus class V
(nonproliferative forms; 26 patients) versus class III plus class
IV (proliferative forms; 85 patients).
4.1. Prevalence of Autoantibodies and Histo Pathological Asso-
ciations. At renal biopsy, high titers of anti-dsDNA were
present in 77.5% of cases, high titers of anti-C1q in 70.5% of
cases, high titers of anti-nucleosome antibodies in 80.3% of
cases, and high titers of anti- ribosome antibodies in 14% of
cases; C3 were low in 82% of cases and C4 in 74% of cases.
Table 2 reports the comparison at time of renal biopsy of
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Table 1: Clinical and histological characteristics at renal biopsy of
the 107 lupus nephritis patients enrolled in the study who received
111 renal biopsies.
Males/females 13/94
Age at diagnosis of renal biopsy
(M ± SD) 36.4 ± 13.9
Duration of SLE years (M ± SD) 5.1 ± 6.5
Serum creatinine mg/dL (M ±
SD) 1.07 ± 0.76
Number of patients with serum
creatinine >1.2mg/dL 31 (28%)
Proteinuria g/24 h (M ± SD) 3.4 ± 2.85
Number of patients with
nephrotic syndrome 44 (39.6%)
Hemoglobin g/dL 11.53 ± 1.9
Class II (number of
patients)/activity
index/chronicity index
8 (7.2%)/1.6 ± 3.2/0.4 ± 0.9
Class III (number of
patients)/activity
index/chronicity index∗
35 (31.5%)/5.3 ± 2.5/1.7 ± 1.74
Class IV (number of
patients)/activity
index/chronicity index∗∗
50 (45%)/9.0 ± 3.2/2.1 ± 1.7
Class V (number of
patients)/activity
index/chronicity index
18 (16.2%)/1.1 ± 2.1/0.7 ± 1.2
Methylprednisolone pulses
0.5–1 g/day for 3 days∗∗∗ 80 (72%)
Oral prednisone 1mg/kg/day for
1 month 31 (28%)
Oral cyclophosphamide
1-2mg/kg/day for 2-3 months§ 36 (32%)
6 fortnightly cyclophosphamide
pulses of of 0.5 g§§ 11 (10%)
6 monthly cyclophosphamide
pulses of 1 g/m2§§§
18 (16%)
Mycophenolate mofetil 2 g/day$ 20 (18%)
Maintenance therapy:
mycophenolate
mofetil/azathioprine
30/21
M, mean; SD, standard deviation. ∗including 15 patients with class III + V;
∗∗including 15 patients with class IV + V; ∗∗∗(1 patient of class II, 27 of class
III, 45 of class IV, and 7 of class V); §(14 patients of class III and 22 of class
IV); §§(3 patients of class III, 6 of class IV, and 2 of class V); §§§(2 patients of
class II, 5 of class III, 10 of class IV, and 1 of class V), $(2 patients of class II, 5
of class III, 8 of class IV, and 5 of class V).
clinical data and of the panel of autoantibodies between pro-
liferative forms (class III plus class IV) and nonproliferative
forms (class II plus class V) of LN. At univariate analysis,
among the clinical parameters, proteinuria (𝑃 = 0.02) and
hemoglobin (𝑃 = 0.0008) and among the immunological
tests, C3 (𝑃 = 0.02) and C4 (𝑃 = 0.02) complement fractions,
anti-DNA (𝑃 = 0.001), anti-C1q (𝑃 = 0.0005), and high titers
of anti-C1q antibodies or of anti-dsDNA antibodies (𝑃 =
0.0000) and anti-nucleosome antibodies (𝑃 = 0.04) were able
to differentiate proliferative from nonproliferative forms of
LN. At multivariate analysis, hemoglobin (𝑃 = 0.008, OR =
0.68, CI: 0.52–0.9) and anti-C1q antibodies (𝑃 = 0.03, OR =
1.004, CI: 1.0003–1.007) were the independent predictors
to discriminate between proliferative versus nonproliferative
lupus nephritis. Excluding clinical parameters, atmultivariate
analysis, logarithm of erythrocyte sedimentation rate (ESR)
(𝑃 = 0.03, OR = 1.9, CI: 1.08–3.42) and high titers of anti-C1q
antibodies or of anti-dsDNA antibodies (𝑃 = 0.005, OR =
8.67, CI: 2.03–37.3) are the independent predictors which are
able to discriminate proliferative from nonproliferative lupus
nephritis. Among patients with proliferative forms of lupus
nephritis, 95% have high titers of anti C1q or of anti-dsDNA
(66.2% have high titers of both anti-C1q and of anti-dsDNA)
while 5% have the results of both tests in a normal range.
Among patients with nonproliferative forms, 64% have high
titers of anti C1q or of anti DNAwhile 36% have the results of
both tests in a normal range (𝑃 = 0.000).
The correlations among the basal clinical and the immu-
nological data and the activity and the chronicty index
at renal biopsy are reported in Table 3. All the clinical
and immunological parameters evaluated with the exception
for C reactive protein (CRP) and anti-ribosome antibodies
showed a significant correlation with activity index. At
multivariate analysis proteinuria (𝑃 = 0.0013), low C4
(𝑃 = 0.0010), and high ESR (𝑃 = 0, 037) were the
independent predictors of the activity index. Excluding the
clinical variables, low C4 (𝑃 = 0.0004) and high ESR (𝑃 =
0, 0025) were the independent predictors of activity index.
In contrast, serum creatinine was the only parameter
among those evaluated that showed a direct correlation with
the chronicity index (𝑅: 0.4, 𝑃 = 0.0000).
4.2. Correlations between Autoantibodies and Clinical Param-
eters. No correlation was found at time of renal biopsy
between serum creatinine and the panel of autoantibodies,
C3 and C4 complement fractions, and ESR and CRP. Among
these tests, anti-C1q only showed a significant direct cor-
relation with the amount of proteinuria (𝑅 = 0.2, 𝑃 =
0.03). In addition, patients with high titers of anti-C1q or
of anti-dsDNA had significant higher proteinuria (median
2.7 g/day, IQ 1.6–4.6) than those with both tests in normal
range (1.8 g/day, IQ 1.0–2.2,𝑃 = 0.05). Anti-C1q, anti-dsDNA,
and ESR were inversely correlated with hemoglobin (R-0.22,
𝑃 = 0.02,𝑅-0,24,𝑃 = 0.01,𝑅-0.32,𝑃 = 0.002, resp.), while C3
and C4 were correlated with hemoglobin (𝑅 0.36, 𝑃 = 0.0002
and 𝑅 0.25, 𝑃 = 0.01).
4.3. Clinical and Immunological Outcome after the Beginning
of Induction Therapy. After renal biopsy and the beginning
of induction therapy, 104 patients had a second evaluation
between 3 and 12 months. Table 4 reported the results of
clinical and immunological tests in patients reevaluated at
3 months, at 6 months, and at 12 months. At 3 months,
serum creatinine was unchanged and proteinuria did not
show a significant improvement, while ESR, C3, anti-DNA,
anti-C1q, and anti-nucleosome antibodies showed a signif-
icant improvement in the median values. At 6 and at 12
months, proteinuria significantly improved together with all
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Table 2: Comparison of clinical and immunological features between nonproliferative forms (class II + class V) and proliferative forms (class
III + class IV) lupus nephritis.
Non proliferative LN
26 patients
Proliferative LN
85 pateints 𝑃
Serum creatinine mg/dL 0.8 (0.67–0.96) 0.9 (0.74–1.15) Ns
Proteinuria g/day 1.94 (1–2.74) 2.8 (1.6–4.7) 0.02
Hemoglobin g/dL 12.9 (11.3–14) 11.2 (9.8–12.3) 0.0008
Activity index 1 (0–3) 7 (5–9) 0.0000
Chronicity index 1 (0–2) 2 (1–3) 0.02
Erythrocyte sedimentation rate
mm 21 (11–46.5) 37.5 (20.7–71.5) 0.07
C reactive protein mg/dL 0.39 (0.08–0.89) 0.3 (0.11–0.6) Ns
C3 mg/dL 72 (60–94) 62 (46.7–80.5) 0.02
C3 <90mg/dL 65% 87.3% 0.08
C4 mg/dL 13 (9–19) 8.5 (5–14) 0.02
C4 <15mg/dL 57.6% 78.8% 0.01
Anti-DNA antibodies U/mL 67 (18–135) 183 (85–400) 0.001
Anti-DNA antibodies U/mL >50 50% 86% 0.001
Anti-C1q antibodies AU 41 (22–123) 216 (63–320) 0.0005
Anti-C1q antibodies AU >55 44% 79% 0.003
Anti-nucleosome Ab U 51 (18.5–97) 95 (44–118) 0.04
Anti-nucleosome antibodies Ab
U >20 68% 84% 0.02
Anti-DNA >50U/mL or anti-C1q
>55 AU 9 (36%) 80 (95%) 0.000
Anti-ribosome antibodies 3 (2–5.5) 2 (2–6) Ns
Anti-ribosome antibodies >20 16% 13% Ns
Lupus anti-coagulant positivity 22.7% 15,4% Ns
Antiphospholipid antibodies 32% 25% Ns
The data are reported as Median and interquartile ranges.
immunological tests with the exception of ESR at 6 months
and anti-ribosome antibodies at 12 months.
Altogether, during the observation period, 39 patients
(37.5%) achieved and 65 (62.5%) did not achieve complete
renal remission (46 were in partial remission, 13 had persis-
tent renal activity, and 6 had persistent nephrotic syndrome).
Clinical and immunological tests at the time of renal biopsy
have been tested as predictors of complete renal remission
(Table 5). At univariate analysis, none of the immunological
tests were predictive of complete remission. At multivariate
analysis, proteinuria (𝑃 = 0.015, OR: 0.76 CI 0.62–0.95) and
the duration of therapy (𝑃 = 0.03OR: 1.19 CI 1.017–1.39) were
the independent predictors of complete renal remission.
5. Discussion
In this study, we have investigated the prevalence and the
value of a panel of autoantibodies (anti-dsDNA, anti-C1q,
anti-nucleosome, and anti-ribosome antibodies) as well as C3
and C4 complement fractions in predicting the activity of LN
at the time of renal biopsy. The most important difference of
our study compared to many previous studies is the timing of
blood sampling in relation to renal activity. As amatter of fact,
in the majority of the studies evaluating the predictive values
of autoantibodies [11, 15, 21–23], the renal activity of LN at the
time of blood sampling was judged by clinical parameters but
not confirmed by renal biopsy. To the best of our knowledge,
only a few studies have evaluated the association of some
autoantibodies with activity of LN at the time of renal biopsy
[24–27]. Trendelenburg et al. [24] reported that all but one
out of 36 patients with proliferative lupus were positive for
anti-C1q at the time of renal biopsy compared with 35%
of patients with inactive LN. In 136 Chinese patients [25],
anti-C1q and anti-dsDNA were more closely correlated with
histological activity of LN at the time of renal biopsy than
anti-extractable nuclear antigen antibodies, anti-C protein
antibodies, anti cardiolipin, and anti Beta2 glycoprotein
antibodies. The combination of anti-C1q and anti-dsDNA
indicates higher renal disease activity and predicts poor long
term renal outcome. Another paper [26] investigated the
clinical and pathological association of anti-C1q in LN and
found ahigher prevalence of the autoantibody in class IV than
in the other histological classes. Among the clinical variables
low haemoglobin was associated with anti-C1q positivity.
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Table 3: Correlations of activity and chronicity index with clinical
and immunological tests.
Activity
index
𝑅
𝑃
Chronicity
index
𝑅
𝑃
Serum creatinine
mg/dL 0.23 0.017 0.4 0.0000
Proteinuria g/day 0.3 0.0014 0.17 0.08
Erythrocyte
sedimentation rate
mm
0.24 0.02 Ns Ns
C reactive protein
mg/dL Ns Ns Ns Ns
C3 mg/dL −0.34 0.0003 Ns Ns
C4 mg/dL −0.28 0.004 Ns Ns
Anti-DNA antibodies
U/mL 0.31 0.001 Ns Ns
Anti-C1q antibodies
AU 0.24 0.01 Ns Ns
Anti-nucleosome
antibodies Ab U 0.29 0.041 Ns Ns
Anti-Ribosome
antibodies Ns Ns Ns Ns
Lupus anticoagulant Ns Ns Ns Ns
Antiphospholipid
antibodies Ns Ns Ns Ns
In this paper, we have shown that there was a significant
difference in the autoantibodies profile between proliferative
forms (class III plus IV) and the other forms of LN (class
V and class ll). All the autoantibodies evaluated, with the
exception of anti-ribosome antibodies, had significant higher
prevalence and higher titres in proliferative than in non-
proliferative forms of LN. C3 and C4 complement fractions
too were significantly lower in proliferative than in nonpro-
liferative LN. At multivariate analysis, considering clinical
and immunological tests, only low haemoglobin and high
anti-C1q were the independent predictors of proliferative
LN. Excluding the clinical variables, high ESR and positive
anti-C1q or anti-dsDNA were able to discriminate between
proliferative and nonproliferative LN. Ninety-five percent of
patients with proliferative LN had high titers of anti C1q or
of anti-dsDNA (66.2% had high titers of both tests) while 4
patients only had the results of both tests in normal range.
The increasing power of the combination of anti-C1q or anti-
dsDNA positivity in predicting the activity of LN has been
reported by other studies [25, 28].
This higher predictive value of anti C1q for proliferative
LN confirmed our findings in a previous study in which we
demonstrated that 80% of flares that developed in patients
with proliferative forms were associated with high titres of
anti-C1q in comparison to only 54% of those that occurred in
the nonproliferative forms [16]. Instead, other cohort studies
did not show differences in the prevalence of antiC1q between
proliferative and nonproliferative lupus nephritis [28–30].
This discrepancy could be due to the fact that in these studies
the diagnosis of renal activity was done on clinical grounds
and not confirmed by renal biopsy. Again, anti-C1q, alone
or associated with anti-dsDNA, was the only test among the
immunological parameters that significantly correlated with
the amount of proteinuria. None of the immunological tests
correlated with serum creatinine but the majority of our
patients had normal renal function, andmany tests correlated
with hemoglobin, a manifestation not specific for LN but an
expression of the general activity of SLE. Low C4 and high
ESR were the independent predictors of a high activity index
at multivariate analysis while none of the tests of the panel
correlated with chronicity index.
In contrast to what was reported by Yang et al. [25], in our
cohort, none of the immunological tests at the time of renal
biopsy was predictive of the renal response, at least in the
short term. However, we have shown that, three months after
the start of the induction therapy and prior to the improve-
ment of proteinuria, a significant reduction of themean value
of anti-C1q, anti-dsDNA, and anti-nucleosome antibody
occurred. The progressive and significant drop in autoanti-
bodies titres continued at 6 and at 12 months together with a
clinical improvement as reported in other studies [24, 26, 31].
Anti-C1q antibodies can be detected by differentmethods
(reviewed in [32, 33]). In the early 1980s, a solid-phase assay
using purified C1q, immobilized on plastic assay plates, was
used for the detection of circulating immune complexes in
SLE patients. To differentiate between immune complexes
and anti-C1q antibodies, high-salt concentrations (0.5–1.0M
sodium chloride) were used. Using this method, the bind-
ing of the globular heads of C1q to immune complexes
is prevented, whereas anti-C1q antibodies can still interact
with the coated C1q. Subsequently, to eliminate the need to
use high-ionic strength buffer, assays have been developed
that utilize only the C1q collagen-like region. The use of
the purified collagen-like region may potentially be more
reliable. However, additional exposed epitopes, by cleaving of
the C1q molecule, might interfere with the results obtained
with this assay. More recently, peptides derived from C1q
that have the properties to detect a major linear epitope in
a high percentage of the patients in the absence of high-
ionic strength buffer has been proposed [33]. Unfortunately,
systematic studies comparing anti-C1q antibody detected
by different assays are not available and different studies
have used different methods. In our study, we have used
the “classic” assay which has been used in the majority of
published clinical studies because it is more readily available.
6. Conclusions
We found a significantly different autoantibodies profile
between proliferative and nonproliferative forms of LN at
the time of renal biopsy. Among the panel of autoantibodies
evaluated in this study, anti-C1q alone or in combinationwith
anti-dsDNA emerged as the most reliable in differentiating
proliferative and nonproliferative LN and anti-C1q is the
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Table 4: Outcome of clinical and immunological parameters at 3, 6, and 12 months after the beginning of induction therapy.
Basal
16 pts At 3 months 𝑃
Basal
46 pts At 6 months 𝑃
Basal
42 pts At 12 months 𝑃
S. Creat. mg/dL 0.760.68–1.6
0.76
0.65–0.89 Ns
0.87
0.7–1
0.85
0.7–1 Ns
0.82
0.67–0.96
0.74
0.67–0.93 Ns
Proteinuria g/day 2.51.8–4
0.94
0.52–4.2 Ns
2.2
1.3–3.9
0.92
0.3–1.5 0.0000
3.0
2.05–4.9
0.51
0.23–1.26 0.0000
ESR mm 6525.7–82
36.5
10.5–51.7 0.04
29.5
12–63.7
21.5
14.2–31.2 Ns
33
20–67
13.5
10.2–32.7 0.0003
CRP mg/dL 0.470.261.1
0.30
0.2–1.32 Ns
0.29
0.09–0.7
0.1
0.06–0.28 0.005
0.31
0.12–0.61
0.1
0.04–0.2 0.005
C3 mg/dL 6760–87
83
74.5–100.5 0.03
73
47.2–87.7
92
79–108 0.0000
63
48–81.2
86.5
71–101.5 0.0000
C4 mg/dL 108–13
13
9–20 Ns
10
5.2–16.7
17
11–21 0.0000
9
5–14.7
13.5
10–20 0.001
Anti-DNA Ab
UmL
79.5
10.0–291
38
11.7–85 0.01
173
69.5.400
71.7
15.7–84.7 0.0000
124
83.7–345
48
34–104 0.0000
Anti-C1q Ab AU 120.552–315
52.5
39–121 0.002
94
35–234
50
22.7–108.5 0.0003
147
56–320
65
35.7–122 0.0000
Anti-nucleosome
Ab
66
42.7–110
58
39–83 0.04
97.5
30–118
41
13–56 0.0001
88
51–109
32
16–70 0.0001
Anti-ribosome Ab 2.51.75–4
2
2-3 Ns
3.5
2–6
2
2–3.5 0.0007
2
2–10
2
2-3 Ns
The data are reported as Median and interquartile ranges: S. = serum, Creat. = creatinine, ESR = erythrocyte sedimentation rate, CPR = C reactive protein, and
Ab = antibodies.
Table 5: Predictors of complete renal remissions among the clinical and the immunological tests at renal biopsy.
Complete remission
39 patients
No complete remission
65 patients 𝑃
Months of therapy 6.0 (5.2–7.4) 5.2 (3.5–6.8) 0.02
Serum creatinine mg/dL 0.83 (0.64–0.95) 0.85 (0.7–1.26) 0.15
Proteinuria g/day 1.96 (12–2.76) 3.45 (2.1–5) 0.0009
Hemoglobin g/dL 12.0 (11.0–12.9) 11.6 (10–12.7) 0.12
Erythrocyte sedimentation rate 33 (17.5–61.2) 39 (16–73) 0.7
C reactive protein mg/dL 0.3 (0.09–1.22) 0.3 (0.14–0.67) 0.6
C3 mg/dL 66 (48–82.2) 70 (48–88) 0.5
C4 mg/dL 9 (5.2–115.7) 10 (5–14) 0.7
Anti DNA antibodies U/mL 147 (83.5–380) 132 (43–400) 0.5
Anti C1q antibodies AU 120 (35–320) 128 (42.5–320) 0.5
Anti-nucleosome antibodies U 88 (57–111) 92.5 (33.2–115.7) 0.8
Anti-DNA >55U/mL or anti-C1q >50 AU antibodies 34 (87%) 58 (89,2%) 1
Anti-ribosome antibodies 2 (2–5.5) 2 (2–5.7) 0.1
The data are reported as Median and interquartile ranges.
only test correlated with the clinical presentation of LN.
After the beginning of therapy, the titer of the autoantibodies
progressively and significantly reduced, but none of them
was predictive of complete renal remission. The results of
this work, which outlines the role of autoantibodies and
in particular of anti-C1q, in defining the activity of lupus
nephritis at the time of renal biopsy, confirm their utility in
diagnosing the acute exacerbations of LN made on clinical
grounds only.
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